Figure S1. CSS curves of different adjuvant therapies. Before putting cytokine and targeted therapy together as one factor (adjuvant therapy), we separately analyzed cytokine therapy and targeted therapy, the results indicated that they both had no significant benefits on CSS compared active surveillance (p = 0.673,χ2 = 0.793). (TIFF 130 kb
Figure S8. (A) Representative images of Western blot analysis of pAKT S473 and pERK T202/Y204 protei...
Table S2.Hazard ratios for OS and PFS based on CCR7 in different subgroups (High vs Low). (DOCX 63Â ...
Additional file 2: Figure S2. Stratification of patients by IMDC and Meet-URO scores at nivolumab tr...
Figure S2. Univariable analysis for the factor of adjuvant therapy. In univariable cox analyses for ...
Figure S1. Representative photographs of CCR7 immunostaining and cut-off point choosing. (A) Tumoral...
Table S1: Multivariate analysis of PFS after controlling for number of prior treatments. Table S2: M...
Figure S1. Sensitivity analysis of the association between TN and CSS outcomes in RCC patients. (TIF...
Table S1a. Median survival (months) by risk group and therapy sequence. Table S1b. Two year overall ...
Figure S1. Kaplan-Meier curves for overall survival in patients stratified for the occurrence of dru...
Figure S1. (A) (PANEL1) Table of 1286 ccRCC patient distribution: 1013 tumor free patients at 36 mon...
Figure S10. (A) Kaplan-Meier curve for the Disease Free Survival (DFS) in the engrafted (Engraf) and...
Table S1.Univariate analyses of characteristics associated with overall survival and progression fre...
Calibration curve: progression-free and overall survival. Predicted data (dotted line) were plotted ...
Figure S2. (A) Hematoxylin and Eosin (H&E) and CD31 staining of formalin-fixed and paraffin- embedde...
Figure S1. Flow chart of included patients. Table S2. Table resuming patients âcharacteristics. Ta...
Figure S8. (A) Representative images of Western blot analysis of pAKT S473 and pERK T202/Y204 protei...
Table S2.Hazard ratios for OS and PFS based on CCR7 in different subgroups (High vs Low). (DOCX 63Â ...
Additional file 2: Figure S2. Stratification of patients by IMDC and Meet-URO scores at nivolumab tr...
Figure S2. Univariable analysis for the factor of adjuvant therapy. In univariable cox analyses for ...
Figure S1. Representative photographs of CCR7 immunostaining and cut-off point choosing. (A) Tumoral...
Table S1: Multivariate analysis of PFS after controlling for number of prior treatments. Table S2: M...
Figure S1. Sensitivity analysis of the association between TN and CSS outcomes in RCC patients. (TIF...
Table S1a. Median survival (months) by risk group and therapy sequence. Table S1b. Two year overall ...
Figure S1. Kaplan-Meier curves for overall survival in patients stratified for the occurrence of dru...
Figure S1. (A) (PANEL1) Table of 1286 ccRCC patient distribution: 1013 tumor free patients at 36 mon...
Figure S10. (A) Kaplan-Meier curve for the Disease Free Survival (DFS) in the engrafted (Engraf) and...
Table S1.Univariate analyses of characteristics associated with overall survival and progression fre...
Calibration curve: progression-free and overall survival. Predicted data (dotted line) were plotted ...
Figure S2. (A) Hematoxylin and Eosin (H&E) and CD31 staining of formalin-fixed and paraffin- embedde...
Figure S1. Flow chart of included patients. Table S2. Table resuming patients âcharacteristics. Ta...
Figure S8. (A) Representative images of Western blot analysis of pAKT S473 and pERK T202/Y204 protei...
Table S2.Hazard ratios for OS and PFS based on CCR7 in different subgroups (High vs Low). (DOCX 63Â ...
Additional file 2: Figure S2. Stratification of patients by IMDC and Meet-URO scores at nivolumab tr...